Significance of unphosphorylated and phosphorylated heat shock protein 27 as a prognostic biomarker in pancreatic ductal adenocarcinoma

Richard Drexler1,2 · Kim C. Wagner1,2 · Mirco Küchler1,2 · Bernd Feyerabend4 · Moritz Kleine3 · Karl J. Oldhafer1,2

Received: 13 December 2019 / Accepted: 2 March 2020 / Published online: 21 March 2020 © The Author(s) 2020

Abstract

Purpose Few studies reported about the potential of unphosphorylated heat shock protein 27 (HSP27) and phosphorylated heat shock protein 27 (pHSP27) as a predictor for survival and gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). In this study, we analysed the expression patterns of pHSP27 and HSP27 in a patient population after surgery and correlated the immunohistochemical results with clinicopathological data and long-term outcome of the patients.

Methods HSP27 and pHSP27 (Ser-15, Ser-78 and Ser-82) protein expression were analysed by immunohistochemistry using the immunoreactive score (IRS) from paraffin-embedded tissue of 106 patients with PDAC who underwent surgery. Immunohistochemical results were correlated with clinicopathological data, disease-free (DFS) and overall survival (OS).

Results HSP27 expression was significantly lower in patients with a shorter OS ($p = 0.006$) and DFS ($p < 0.0001$). A higher HSP27 expression was associated with a better response to gemcitabine in the resected, non-metastasised patients group ($p = 0.001$). Furthermore, HSP27 was downregulated in patients suffering from metastases at time of surgery ($p < 0.001$) and in undifferentiated tumours ($p = 0.007$). In contrast, pHSP27-Ser15, -Ser78 and -Ser82 were not associated with any survival data of the study population.

Conclusion HSP27 seems to be a strong indicator for the prediction of OS and DFS. Moreover, HSP27 could play a role in the formation and migration of liver metastases of PDAC.

Keywords Heat shock protein · HSP27 · Pancreatic cancer · Metastasis · Biomarker · HSP

Introduction

PDAC remains a challenging disease with a poor overall 5-year survival rate between 4 and 8% (Ilic and Ilic 2016; Ferlay et al. 2013). The best chance for cure with long-term survival is surgical resection. Unfortunately, the majority of the patients display hepatic metastasis at time of diagnosis and only 15–20% are eligible for surgery (Siegel et al. 2018; Vincent et al. 2011).

Heat shock proteins (HSPs) were first discovered by Ritossa et al. as a family of proteins induced by heat shock and other stimuli (Lindquist and Craig 1988; Michel and Starka 1986). These proteins have been characterized as chaperones which are capable of modifying structures of several proteins and can prevent accumulation of misfolded proteins (Ritossa 1996; Gaestel et al. 1991; Butt et al. 2001; Döppler et al. 2005). The effect
of phosphorylation is a conformational change of HSP27 which leads to dissociation of large oligomers and the formation of dimers presenting the active leading conformation (Jovcevski et al. 2015).

The phosphorylated and unphosphorylated form of HSP27 has been linked to tumour progression and cell migration (Cayado-Gutiérrez et al. 2013; Zoubeidi and Gleave 2012). Therefore, the expression of HSP27 has been shown to be related to tumour characteristics. Consecutively, the potential of HSP27 in diagnostic, prognostic or treatment implications have been examined in multiple tumour entities. Overexpression of HSP27 correlates with a shorter overall survival (OS) or disease-free survival (DFS) in ovarian, gastric, prostate cancer, and osteosarcoma (Piura et al. 2002; Elpek et al. 2003; Takeno et al. 2001; Bostwick 2000; Uozaki et al. 2000). In contrast, a higher expression is associated with a longer OS in endometrium, oesophageal cancer and malignant fibrous histiocytoma (Geisler et al. 1999; Nakajima et al. 2002; Têtu et al. 1992). These results indicate that HSP27 might serve as a reliable biomarker in human cancer but must be considered separately for every tumour entity (Ciocca and Calderwood 2005).

Only a few clinical studies are available which investigated the potential of HSP27 and pHSP27 to predict survival in PDAC. However, the results are inconsistent or even contradictory (Schäfer et al. 2012; Kawano et al. 2018; Tsi-aousidou et al. 2013; Okuno et al. 2016). Therefore, it is still questionable whether HSP27 could be used as a biomarker in PDAC.

Furthermore, weak points of these published studies are reduced numbers of patients and lack of clinical data. Since almost all patients with PDAC receive adjuvant chemotherapy, survival could also be influenced by chemotherapy resistance. HSP27 and pHSP27 are shown to be involved in tumour suppression and resistance to chemotherapy with gemcitabine in pancreatic cancer (Guo et al. 2015; Mori-Iwamoto et al. 2007; Kuramitsu et al. 2012; Liu et al. 2012; Taba et al. 2011). pHSP27, which is induced by gemcitabine, is reported to play an important role in the suppression of cancer cell growth in pancreatic cancer cell lines (Taba et al. 2010; Nakashima et al. 2011). However, it is well known that adjuvant therapy with modified FOLFIRINOX results in a longer OS when compared with gemcitabine (Conroy et al. 2018; Yang et al. 2019). Recent evidence indicates that HSP27 could take a significant role in treatment response to mFOLFIRINOX in PDAC. As the mFOLFIRINOX regimen consists of oxaliplatin, irinotecan, 5-fluorouracil and leucovorin, previous studies showed a higher sensitivity for irinotecan and 5-fluorouracil in colon cancer when HSP27 is suppressed (Choi et al. 2007; Hayashi et al. 2012; Shamada et al. 2018). In addition, the inhibition of HSP90 improves the efficacy of oxaliplatin in p53-deficient colon cancer cells (Moser et al. 2007).

In the present study, both HSP27 and pHSP27 were analysed in a patient population diagnosed with PDAC and its expression was correlated with clinicopathological data including OS and DFS.

Materials and methods

Ethics approval

All patients’ data were fully anonymised, and the study was performed, according to the standards set in the Declaration of Helsinki 1975. The tumour tissue used was leftover material that had initially been collected for diagnostic purposes. All diagnostic procedures have already been fully completed when samples were retrieved for the study. The study was approved by the Ethics Committee of the Medical Chamber (“Ärztekammer”), Hamburg, Germany (approval number PV5510).

Patients

A total of 106 patients (female, n = 50; male, n = 56; median age, 67.2 years [IQR 56.9–76.4 years]) who had been diagnosed with PDAC and went through surgery between 2010 and 2018 were included. Patients' demographic and clinicopathological characteristics are shown in Table 2. The diagnosis was histologically confirmed and TNM classification was assessed according to AJCC 7th edition. The R-status was obtained pathologically via circumferential resection margin. All patients had a follow-up either until death (n = 76) or until their most recent contact (n = 28) on August 31, 2019.

Immunohistochemical analysis

Immunohistochemistry was used to determine the intracellular localization and expression of HSP27 and pHSP27 (Ser-15, Ser-78 and Ser-82). Immunohistochemical staining was performed using paraffin-embedded tissue. Tissue sections (4 µm) were deparaffinized in xylene and rehydrated in a descending alcohol set followed by heated antigen retrieval with 10 mM sodium citrate buffer (pH 6.0) for five minutes. Coverplates™ (ThermoFisher Scientific) were used. Endogenous peroxidase activity was quenched with Peroxide Block (Zytomed Systems). Primary anti-HSP27 monoclonal antibody (working dilution 1:500, Abcam (UK), ab2790) and anti-phosphorylated-HSP27-antibodies (Abcam (UK), Ser15: working dilution 1:350, ab76313; Ser78: working dilution 1:900, ab32501; Ser82: working dilution 1:700, ab90537) were diluted with Antibody Diluent (Zytomed Systems). Sections were covered with antibody and incubated at 4 °C for 24 h. Subsequently, ZyroChem Plus (HRP) Polymer
Bulk Kit (Zytomed Systems) were used before staining with DAB (diaminobenzidine) Substrate Kit (Zytomed Systems). Gill’s hematoxylin III (Carl Roth) was used as a counterstaining agent, including a 10 s hydrochloric acid bath (5%) for differentiation. Sections were then dehydrated and mounted with EcoMount (Zytomed Systems).

Methods of evaluation

An immunoreactive score (IRS) was implemented for the evaluation of the HSP27 expression based on the intensity and quantity of immune staining in pancreatic cancer cells. The IRS score was applied as first described by Kaemmerer et al. (2012) and Remmele and Stegner (1987). The intensity of staining was graded as negative (0), mild (1), moderate (2) and intense (3). The percentage of positive cells was evaluated as 0 (no positive cells), 1 (<10% positive cells), 2 (10–50% positive cells), 3 (51–80% positive cells) and 4 (>80% positive cells). The IRS score was obtained by multiplying these two individual scores. As a result, every tissue sample was classified into negative (IRS points 0–1), weak (2–3), mild (4–8) or strong (9–12). Breast carcinoma was used as positive control and brain tissue as negative control. The evaluation of the protein expression was performed by two independent reviewers without knowledge of the patient characteristics.

Statistical analysis

Differences in continuous variables were analysed with Mann–Whitney U test and differences in proportions with chi-square-test or Fisher exact test. DFS and OS was analysed using the Kaplan–Meier method. Univariate and multivariate Cox proportional hazards models were used to assess the effects of variables on OS and DFS. A two-sided p-value less than 0.05 was considered as statistically significant. All analyses were performed using SPSS Inc. (Chicago, IL, USA).

Results

Immunohistochemical analysis in PDAC and normal tissue

A positive IRS score of HSP27 with various interindividual intensity was found in the cytoplasm of pancreatic cancer cells in 65 patients (61.3%). Nuclear staining was not detected. Expression of HSP27 was classified into four grades according to the IRS score (negative, mild, moderate and strongly positive; Table 1). 23 patients (21.7%) had a strongly positive staining. We found a significant difference of HSP27 expression between cancer cells and normal pancreatic tissue ($p < 0.001$). In 79 (74.5%) of the corresponding 106 normal pancreatic tissues, HSP27 expression was positive whereof 43 (40.6%) showed a strongly positive staining. In contrast, the majority of patients had a negative IRS score for pHSP27-Ser15 (82 patients, 77.4%) and pHSP27-Ser78 (69 patients, 65.1%). Of the corresponding normal pancreatic tissue, 67 patients (63.2%) were pHSP27-Ser15-negative ($p = 0.012$) and 52 patients (49.1%) pHSP27-Ser78-negative ($p > 0.001$). However, only 48 patients (45.3%) had a negative IRS score for pHSP27-Ser82 in pancreatic cancer cells with 35 patients (33.0%) being negative in corresponding normal pancreatic tissue ($p > 0.001$).

Correlation of HSP27 and pHSP27 with clinicopathological features

No significant differences were found between HSP27 expression and gender, age, tumour localization, pathological and lymph node status (Table 2). However, metastasised patients ($n = 40$) showed a significantly lower expression of

| IRS-points | IRS-classification |
|------------|--------------------|
| 0–1        | $0 = \text{negative}$ |
| 2–3        | $1 = \text{positive, weak expression}$ |
| 4–8        | $2 = \text{positive, mild expression}$ |
| 9–12       | $3 = \text{positive, strong expression}$ |
HSP27 ($p < 0.001$). Of these 40 patients, 32 (80.0%) had a negative IRS score, whereas no patient had a strongly positive score.

The metastasised subpopulation included 34 patients with liver metastasis (85.0%), 3 patients with peritoneal carcinomatosis (7.5%) and 3 patients with distant lymph node metastasis (7.5%). In contrast, 57 patients (86.4%) within the non-metastasised group expressed HSP27, 23 patients (40.1%) with a strongly positive IRS score.

Furthermore, a lower IRS score for HSP27 was significantly correlated with a bigger tumour size ($p = 0.044$), a less differentiated tumour ($p = 0.007$) and lymphatic invasion ($p = 0.013$). The group of patients with a positive IRS score

| Characteristic                        | $n = 106$ | HSP27 | pHSP27-Ser15 | pHSP27-Ser78 | pHSP27-Ser82 |
|--------------------------------------|-----------|-------|-------------|-------------|-------------|
|                                      |           | 0     | 1 | 2 | 3 | $p$ | 0 | 1 | 2 | 3 | $p$ | 0 | 1 | 2 | 3 | $p$ | 0 | 1 | 2 | 3 | $p$ |
| Gender                               |           |       |              |             |             |
| Female                               | 50        | 14    | 9 | 15 | 12 | 0.073 | 36 | 8 | 6 | 0 | 0.266 | 30 | 9 | 6 | 5 | 0.520 | 18 | 13 | 16 | 3 | 0.237 |
| Male                                 | 56        | 27    | 11 | 7 | 11 |       | 46 | 7 | 2 | 1 |       | 39 | 8 | 7 | 2 |       | 30 | 12 | 10 | 4 |       |
| Tumour localization                  |           |       |              |             |             |
| Head                                 | 80        | 30    | 13 | 19 | 18 | 0.798 | 63 | 10 | 6 | 1 | 0.756 | 54 | 9 | 12 | 5 | 0.016 | 36 | 16 | 23 | 5 | 0.084 |
| Body                                 | 7         | 3     | 2 | 0 | 1 |       | 6  | 0 | 1 | 0 |       | 2  | 3 | 0 | 2 |       | 3  | 2 | 1 | 1 |       |
| Tail                                 | 11        | 5     | 3 | 1 | 2 |       | 7  | 4 | 0 | 0 |       | 9  | 2 | 0 | 0 |       | 5  | 5 | 0 | 1 |       |
| Body + tail                          | 8         | 3     | 2 | 2 | 1 |       | 6  | 1 | 1 | 0 |       | 4  | 3 | 1 | 0 |       | 4  | 2 | 2 | 0 |       |
| Tumour sizea                         |           |       |              |             |             |
| $< 3.5$ cm                           | 45        | 16    | 6 | 10 | 13 | 0.044 | 34 | 6 | 4 | 1 | 0.758 | 30 | 4 | 7 | 4 | 0.052 | 18 | 11 | 12 | 4 | 0.527 |
| $> 3.5$ cm                           | 39        | 17    | 11 | 7 | 4 |       | 32 | 4 | 3 | 0 |       | 29 | 8 | 2 | 0 |       | 18 | 12 | 8 | 1 |       |
| Tumour pathological stage            |           |       |              |             |             |
| T1                                   | 7         | 1     | 1 | 2 | 3 | 0.491 | 6  | 1 | 0 | 0 | 0.675 | 4  | 3 | 0 | 0 | 0.271 | 2  | 1 | 2 | 2 | 0.025 |
| T2                                   | 11        | 6     | 0 | 2 | 3 |       | 7  | 2 | 2 | 0 |       | 5  | 3 | 1 | 2 |       | 5  | 1 | 2 | 3 |       |
| T3                                   | 76        | 30    | 16 | 14 | 16 |       | 57 | 12 | 6 | 1 |       | 50 | 10 | 11 | 5 |       | 34 | 21 | 20 | 1 |       |
| T4                                   | 12        | 4     | 3 | 4 | 1 |       | 12 | 0 | 0 | 0 |       | 10 | 1 | 1 | 0 |       | 7  | 2 | 2 | 1 |       |
| Nodal status                         |           |       |              |             |             |
| N0                                   | 24        | 7     | 4 | 5 | 8 | 0.738 | 16 | 4 | 4 | 0 | 0.421 | 12 | 5 | 4 | 3 | 0.468 | 7  | 6 | 7 | 4 | 0.091 |
| N1                                   | 75        | 30    | 15 | 16 | 14 |       | 59 | 11 | 4 | 1 |       | 52 | 10 | 9 | 4 |       | 36 | 19 | 18 | 2 |       |
| N2                                   | 7         | 4     | 1 | 1 | 1 |       | 7  | 0 | 0 | 0 |       | 10 | 1 | 1 | 0 |       | 7  | 2 | 2 | 1 |       |
| Metastasis status                    |           |       |              |             |             |
| M0                                   | 66        | 9     | 14 | 20 | 23 | <0.001 | 48 | 9 | 8 | 1 | 0.113 | 41 | 10 | 9 | 6 | 0.526 | 26 | 15 | 19 | 6 | 0.228 |
| M1                                   | 40        | 32    | 6 | 2 | 0 |       | 34 | 6 | 0 | 0 |       | 28 | 7 | 4 | 1 |       | 22 | 10 | 7 | 1 |       |
| Tumour differentiation              |           |       |              |             |             |
| Well-differentiated                  | 7         | 0     | 0 | 2 | 5 | 0.007 | 4  | 3 | 0 | 0 | 0.413 | 3  | 2 | 2 | 0 | 0.615 | 3  | 1 | 1 | 2 | 0.174 |
| Moderately differentiated            | 25        | 6     | 5 | 8 | 6 |       | 20 | 2 | 3 | 0 |       | 18 | 4 | 1 | 2 |       | 8  | 9 | 7 | 1 |       |
| Poorly differentiated                | 67        | 30    | 15 | 10 | 12 |       | 54 | 8 | 4 | 1 |       | 42 | 10 | 10 | 5 |       | 32 | 13 | 18 | 4 |       |
| Anaplastic                           | 7         | 5     | 0 | 2 | 0 |       | 4  | 2 | 1 | 0 |       | 6  | 1 | 0 | 0 |       | 5  | 2 | 0 | 0 |       |
| Resection margin                     |           |       |              |             |             |
| R0                                   | 68        | 20    | 10 | 19 | 19 | 0.003 | 49 | 11 | 7 | 1 | 0.296 | 41 | 10 | 10 | 7 | 0.126 | 26 | 15 | 20 | 7 | 0.046 |
| R1                                   | 38        | 21    | 10 | 3 | 4 |       | 33 | 4 | 1 | 0 |       | 28 | 7 | 3 | 0 |       | 22 | 10 | 6 | 0 |       |
| Lymphatic invasion                   |           |       |              |             |             |
| L0                                   | 40        | 8     | 8 | 11 | 13 | 0.013 | 30 | 6 | 3 | 1 | 0.630 | 22 | 6 | 7 | 5 | 0.118 | 16 | 9 | 11 | 4 | 0.619 |
| L1                                   | 66        | 33    | 12 | 11 | 10 |       | 52 | 9 | 5 | 0 |       | 47 | 11 | 6 | 2 |       | 32 | 16 | 15 | 3 |       |

IRS score is classified as 0 (negative), 1 (positive, weak expression), 2 (positive, mild expression) and 3 (positive, strong expression). All statistically significant variables are highlighted in bold. Statistical analysis: Chi-square test

aData not available for 22 patients (20.7%).
was more likely to achieve a negative resection margin in surgery \( (p = 0.003) \).

Immunohistochemical staining of pHSP (Ser-15, Ser-78 and Ser-82) showed a significantly higher IRS score for pHSP27-Ser82 compared to the other sites Ser-78 and Ser-15 in all patients \( (p < 0.001) \). When correlating the expression of each Serin-site of pHSP27 with clinicopathological characteristics, we observed a significantly lower pHSP-Ser82 expression in patients with a higher pathological T-stage \( (p = 0.025) \). In addition, the pHSP27-Ser82 expression was significantly associated with a negative resection margin and the pHSP27-Ser78 expression correlated with the tumour localization \( (p = 0.016, \text{Table } 2) \). We could not find a significant correlation between the pHSP27-Ser15 expression and any clinicopathological feature.

**Expression of HSP27 in liver metastasis**

26 PDAC patients with synchronous liver metastasis were analysed. Liver metastases as the corresponding primaries showed a negative or weakly positive IRS score for HSP27 expression. Most importantly, we observed similar HSP27 expression in the metastases compared to the primary tumours \( (p = 0.821) \). None of the examined metastases showed a mildly or strongly positive expression. Similar results were found for all forms of pHSP27.

**HSP27 and long-term outcome**

On August 31, 2019, 28 patients were still alive. In 77 patients, data regarding time and type of recurrence were available.

Using Kaplan–Meier analysis, we found a significant correlation between the HSP27 expression and outcome of the patients. Patients with a mildly or strongly positive HSP27 tumour had a significant better outcome regarding the OS \( (\text{Fig. } 1a, p < 0.0001) \) and DFS \( (\text{Fig. } 2a, p = 0.006) \) than those with a negative or weakly positive expression.

The median OS of patients with a mildly and strongly positive expression was 28.4 months and 28.0 months, respectively. In contrast, patients with HSP27-negative tumours had a median OS of 10.0 months. Nearly similar results were observed for the DFS with a median of 9.0 months in HSP27-negative tumours and 7.0 months in patients with weakly positive pHSP27 expression. The median DFS was significantly longer in patients with mildly positive (25.0 months) and strongly positive (19.0 months) HSP27 expression. We could not observe significant differences for any phosphorylated form of HSP27 \( (\text{Fig. } 1b–d, \text{Fig. } 2b–d) \).

We performed multivariate analysis using Cox proportional hazards model to investigate whether the expression of HSP27 or pHSP27 was an independent factor for the outcome after surgery. The results showed that only HSP27 functions as an independent marker for the outcome after surgery. The group with no expression of HSP27 and a significant shorter DFS formed liver metastasis as type of recurrence in 80.0% of the cases compared to 53.3% in the patients group with a positive HSP27 expression \( (p = 0.029) \).

**HSP27 as a predictor for gemcitabine sensitivity**

We created a subpopulation of 66 resected, non-metastasised and gemcitabine-treated patients. In this patients group, we investigated the influence of the HSP27 expression on the OS \( (\text{Fig. } 3a–d) \). Kaplan–Meier analysis revealed a significantly better outcome of patients with a mildly or strongly positive HSP27 expression compared to those with a negative or weakly positive IRS score \( (p = 0.001) \). In addition, we applied Kaplan–Meier analysis for all forms of pHSP27 (Ser-15, Ser-78 and Ser-82) but could not find any significant differences \( (\text{Fig. } 3b, c) \).

**Discussion**

Previous studies investigated the potential of HSP27 and pHSP27 as a prognostic biomarker in several tumour entities and found different results \( (\text{Love and King } 1994; \text{Têtu et al. } 1995; \text{Eto et al. } 2016; \text{Elpek et al. } 2003; \text{Takeno et al. } 2001; \text{Uozaki et al. } 2000) \). Therefore, HSP27 and pHSP27 expression and their role as a prognostic biomarker should be investigated separately for each cancer type.

Particularly for PDAC, only three clinical studies are available in the literature. Schäfer et al. \( (2012) \) and Okuno et al. \( (2016) \) used both the unphosphorylated and phosphorylated (-Ser82) form of HSP27. However, Schäfer et al. investigated the protein expression in tissue specimens from patients who underwent surgery, while Okuno et al. used biopsied pancreatic cancer tissue. Another study by Tsi- aouisou et al. \( (2013) \) analysed only the unphosphorylated form of HSP27. To our knowledge, our study is the largest with 106 patients and the only one considering the unphosphorylated as well as all phosphorylated (Ser-15, Ser-78, Ser-82) forms of HSP27.
The aforementioned study by Schäfer et al. (2012) found a significant longer OS in 86 patients with a higher expression of unphosphorylated form of HSP27. In addition, Okuno et al. (2016) correlated a higher pHSP27-Ser82 expression with a longer OS in 49 patients. Our study, does confirm the findings of the study by Schäfer et al. as we found a significant longer OS in patients with mildly or strongly positive expression. However, we could not find any significant correlation between the expression of pHSP27 and outcome of the patients.

Furthermore, our study revealed a significant shorter DFS of patients with negative or weakly positive expression of the unphosphorylated HSP27 and multivariate analyses determined the HSP27 expression as an independent factor for DFS. Taking a closer look at the patients group suffering from a recurrence shows that patients with HSP27-negative tumours had a significantly higher incidence of liver metastases as a type of recurrence. To our knowledge, no study ever before had investigated the link between HSP27 and time as well as type of recurrence.

Therefore, the HSP27 expression seems to have the potential to predict not only the long-term outcome regarding OS and DFS but also the type of recurrence. Combining these results with those of Schäfer et al. concerning the
findings for the OS it is obvious that tumours with a lower HSP27 expression are accompanied with a poor outcome of patients with PDAC.

One reason for a longer survival of patients with HSP27-positive tumours could be a higher sensitivity against adjuvant chemotherapy with gemcitabine.

Mori-Iwamato et al. (2007) investigated HSP27 as one of the target proteins of gemcitabine using proteomic analysis. Furthermore, there is evidence for pancreatic cancer cell lines that overexpression of HSP27 enhanced the sensitivity towards gemcitabine (Guo et al. 2015). While Guo et al. found the unphosphorylated form of HSP27 as an essential component for gemcitabine sensitivity, another study by Kang et al. (2015) described the ratio of phosphorylated to non-phosphorylated HSP27 as more important than the cellular level of HSP27 itself. In addition, Nakashima et al. (2011) suggest the phosphorylation status of HSP27 as an essential determinant for gemcitabine-induced suppression DFS of 21.0 months (log-rank p value: 0.489). c pHSP27-Ser78: The expression of pHSP27-Ser78 is no predictor for the DFS with a comparable median DFS for all expression groups (negative: 10.0 months, weakly positive: 5.8 months, mildly positive: 11.0 months, strongly positive, 10.0 months, log-rank p value: 0.794) d pHSP27-Ser82: The median DFS was 11.0 months in patients with a negative expression, as compared with 10.2 months for a strongly positive expression with a non-significant log rank p value of 0.180

Fig. 2 Correlation of HSP27 expression with disease-free survival. a HSP27: The median DFS was significantly longer in patients with a strongly (19.0 months) and mildly (25.0 months) positive expression when compared with a negative (9.0 months) and weakly positive (7.0 months) HSP27 expression (log-rank p value: 0.006). b pHSP27-Ser15: The median DFS was 9.4 months in patients with a negative as well as mildly positive expression of pHSP27-Ser15. Furthermore, the patients group with a weakly positive expression had a median DFS of 21.0 months (log-rank p value: 0.489). c pHSP27-Ser78: The expression of pHSP27-Ser78 is no predictor for the DFS with a comparable median DFS for all expression groups (negative: 10.0 months, weakly positive: 5.8 months, mildly positive: 11.0 months, strongly positive, 10.0 months, log-rank p value: 0.794) d pHSP27-Ser82: The median DFS was 11.0 months in patients with a negative expression, as compared with 10.2 months for a strongly positive expression with a non-significant log rank p value of 0.180.
Table 3  Cox proportional hazard model for overall survival (n = 106)

| Variable                        | No | Median OS [months] | Univariate | Multivariate |
|---------------------------------|----|--------------------|------------|--------------|
|                                 |    |                    | Univariate |              |
|                                 |    |                    | Hazard ratio (95% CI) | p value | Hazard ratio (95% CI) | p value |
| HSP27 expression                |    |                    |            |              |
| Negative                        | 41 | 10.0               | 1.00       |              |
| Positive, weak                  | 20 | 12.1               | 2.52 (0.87–7.24) | 0.017 | 2.99 (1.12–7.99) | 0.029 |
| Positive, mild                  | 22 | 28.4               | 1.57 (0.66–3.75) | 0.313 | 1.98 (0.90–4.37) | 0.048 |
| Positive, strong                | 23 | 28.0               | 1.01 (0.43–2.45) | 0.956 | 1.01 (0.45–2.28) | 0.973 |
| pHSP27-Ser15 expression         |    |                    |            |              |
| Negative                        | 82 | 18.0               | 1.00       |              |
| Positive, weak                  | 15 | 23.0               | 1.04 (0.08–13.6) | 0.979 | 1.26 (0.05–31.8) | 0.890 |
| Positive, mild                  | 8  | 22.5               | 0.54 (0.03–8.6) | 0.662 | 0.69 (0.02–28.5) | 0.842 |
| Positive, strong                | 1  | 13.0               | 1.25 (0.07–22.9) | 0.879 | 4.96 (0.12–213.5) | 0.404 |
| pHSP27-Ser78 expression         |    |                    |            |              |
| Negative                        | 69 | 16.0               | 1.00       |              |
| Positive, weak                  | 17 | 14.0               | 0.71 (0.17–3.1) | 0.652 | 1.94 (0.24–15.6) | 0.532 |
| Positive, mild                  | 13 | 25.0               | 1.03 (0.14–7.54) | 0.975 | 0.95 (0.08–10.9) | 0.966 |
| Positive, strong                | 7  | 19.0               | 0.56 (0.12–2.59) | 0.460 | 0.58 (0.06–5.61) | 0.636 |
| pHSP27-Ser82 expression         |    |                    |            |              |
| Negative                        | 48 | 21.5               | 1.00       |              |
| Positive, weak                  | 25 | 17.0               | 0.80 (0.14–4.67) | 0.807 | 1.79 (0.16–19.6) | 0.635 |
| Positive, mild                  | 26 | 18.0               | 1.52 (0.27–8.69) | 0.635 | 7.08 (0.42–118.5) | 0.174 |
| Positive, strong                | 7  | 19.0               | 2.29 (0.37–14.4) | 0.376 | 11.7 (0.61–227.1) | 0.104 |
| Gender                          |    |                    |            |              |
| Male                            | 56 | 17.8               | 1.00       |              |
| Female                          | 50 | 14.6               | 1.47 (0.85–2.54) | 0.172 | 1.04 (0.47–2.11) | 0.809 |
| Tumour size*                    |    |                    |            |              |
| < 3.5 cm                        | 45 | 19.0               | 1.00       |              |
| > 3.5 cm                        | 39 | 11.8               | 0.83 (0.46–1.50) | 0.534 | 0.84 (0.45–1.59) | 0.601 |
| Tumour pathological stage       |    |                    |            |              |
| T1                              | 7  | 25.0               | 1.00       |              |
| T2                              | 11 | 14.0               | 0.24 (0.03–1.98) | 0.234 | 0.25 (0.05–1.28) | 0.097 |
| T3                              | 76 | 14.0               | 0.45 (0.11–1.79) | 0.255 | 0.38 (0.10–1.41) | 0.145 |
| T4                              | 12 | 18.2               | 0.79 (0.37–1.72) | 0.565 | 0.70 (0.34–1.43) | 0.329 |
| Nodal status                    |    |                    |            |              |
| N0                              | 24 | 23.0               | 1.00       |              |
| N1                              | 75 | 16.4               | 0.44 (0.09–2.0) | 0.287 | 0.453 (0.13–1.26) | 0.224 |
| N2                              | 7  | 9.0                | 0.91 (0.24–3.39) | 0.886 | 0.747 (0.23–2.44) | 0.629 |
| Metastasis status               |    |                    |            |              |
| M0                              | 66 | 19.5               | 1.00       |              |
| M1                              | 40 | 11.5               | 0.92 (0.39–2.2) | 0.852 | 1.12 (0.47–2.67) | 0.798 |
| Tumour differentiation          |    |                    |            |              |
| Well-differentiated             | 7  | 33.0               | 1.00       |              |
| Moderately differentiated       | 25 | 21.2               | 1.09 (0.17–6.91) | 0.926 | 1.11 (0.23–5.43) | 0.902 |
| Poorly differentiated           | 67 | 14.6               | 1.07 (0.29–3.88) | 0.923 | 0.98 (0.45–3.39) | 0.983 |
| Anaplastic                      | 7  | 9.2                | 1.36 (0.41–4.55) | 0.613 | 1.24 (0.45–3.39) | 0.681 |
| Resection margin                |    |                    |            |              |
| R0                              | 68 | 18.0               | 1.00       |              |
| R1                              | 38 | 14.0               | 0.66 (0.34–1.29) | 0.230 | 1.19 (0.67–2.14) | 0.551 |
| Lymphatic invasion              |    |                    |            |              |
| L0                              | 40 | 24.2               | 1.00       |              |
of pancreatic cancer cells. In our study, we investigated a subpopulation of 66 non-metastasised and resected patients which were treated with gemcitabine as adjuvant chemotherapy. The Kaplan–Meier analysis clearly shows a worse survival in patients with negative or weakly positive HSP27 expression compared to those with a mildly or strongly positive protein expression. Similar results could already be shown by Schäfer et al. (2012) where a negative HSP27 expression was associated with a shorter OS in gemcitabine-treated patients. Therefore, the influence of HSP27 towards the sensitivity of gemcitabine has a huge impact on the survival of resected patients. Even though Nakashima et al. and Kang et al. reported about the significance of phosphorylated forms of HSP27 regarding the effect of gemcitabine, our study does not show a significant correlation between pHSP27 and survival in the gemcitabine-treated subpopulation. Another finding of our study was the downregulation of HSP27 in patients suffering from simultaneous metastases. The downregulation was also found in their relating liver metastases. These results indicate a possible role of HSP27 in the formation of liver metastases. Taken together with the correlation of a low HSP27 expression and liver metastases as a type of an early disease recurrence, we hypothesize that the downregulation of HSP27 could be one of the underlying mechanisms for the migration of pancreatic cancer cells in the liver. Previous studies already tried to investigate the specific impact of HSP27 in formation of metastasis of different cancer types. It is reported that HSP27 can increase transforming growth factor b (TGF-b)-stimulated MMP2 activity and therefore promotes cell invasion in prostate cancer (Xu et al. 2006). In addition, HSP27 modulates the expression of phosphatase and tensin homolog (PTEN) by which the PI3-kinase pathway is influenced in breast cancer (Cayado-Gutiérrez et al. 2013). Furthermore, Vahid et al. (2016) revealed an interaction between HSP27 and the pro-metastatic Hippo pathway in prostate, breast and lung cancer but the impact of this regulation on migration of metastasis needs to be elucidated. At this time, we do not understand the specific mechanisms how the activity and expression of HSP27 is regulated during the formation of metastasis and, consequently which targets are influenced (Wu et al. 2017). Nevertheless, our results show that HSP27 could act as an important factor in metastatic invasion which comes along with a poor outcome of patients with PDAC.

### Conclusion

To conclude, our study demonstrates that a downregulation of HSP27 is associated with a poor outcome for patients with PDAC and therefore HSP27 could serve as a predictor for the OS and DFS. Furthermore, patients with stronger HSP27 expression seem to have a higher sensitivity for gemcitabine resulting in a longer OS. Beside this, patients with a negative HSP27 expression were either presenting simultaneous liver metastasis at time of surgery or developed mainly liver metastasis after surgical resection of the primary tumour within a short time. Therefore, the impact of HSP27 in formation of liver metastasis is obvious but the underlying mechanisms and involvement of specific pathways need to be elucidated in further studies.

### Table 3 (continued)

| Variable             | No | Median OS [months] | Univariate Hazard ratio (95% CI) | p value | Multivariate Hazard ratio (95% CI) | p value |
|----------------------|----|--------------------|----------------------------------|---------|-----------------------------------|---------|
| L1                   | 66 | 14.0               | 1.15 (0.62–2.13)                 | 0.721   | 1.21 (0.61–2.39)                  | 0.584   |
| Perineural invasion  |    |                    |                                  |         |                                   |         |
| Pn0                  | 9  | 25.0               | 1.00                             | 1.00    |                                   | 1.00    |
| Pn1                  | 97 | 16.0               | 0.81 (0.28–2.34)                 | 0.693   | 1.40 (0.55–3.60)                  | 0.480   |
| Vascular invasion    |    |                    |                                  |         |                                   |         |
| V0                   | 50 | 20.5               | 1.00                             | 1.00    |                                   | 1.00    |
| V1                   | 56 | 14.0               | 1.15 (0.62–2.13)                 | 0.658   | 0.68 (0.39–1.19)                  | 0.184   |

CI confidence interval. All statistically significant variables are highlighted in bold.

*Data not available for 22 patients (20.7%)*
### Table 4: Cox proportional hazard model for disease-free survival (n = 77)

| Variable                          | No | Median DFS [months] | Univariate      | Multivariate     |
|-----------------------------------|----|---------------------|-----------------|-----------------|
|                                   |    |                     | Hazard ratio (95% CI) | p value | Hazard ratio (95% CI) | p value |
| **HSP27 expression**              |    |                     |                  |        |                  |        |
| Negative                          | 31  | 9.0                 | 1.00             |        | 1.00              |        |
| Positive, weak expression         | 15  | 7.0                 | 2.84 (0.79–10.1) | **0.017** | 5.55 (1.39–22.0) | **0.015** |
| Positive, mild expression         | 15  | 25.0                | 2.89 (0.88–9.59) | **0.042** | 3.67 (1.04–12.9) | **0.044** |
| Positive, strong expression       | 16  | 19.0                | 1.46 (0.45–4.79) | 0.533   | 2.88 (0.78–10.7)  | 0.113   |
| **pHSP27-Ser15 expression**       |    |                     |                  |        |                  |        |
| Negative                          | 60  | 9.0                 | 1.00             |        | 1.00              |        |
| Positive, weak expression         | 12  | 22.0                | 0.96 (0.07–12.8) | 0.974   | 0.70 (0.02–27.4)  | 0.850   |
| Positive, mild expression         | 4   | 14.0                | 0.27 (0.02–4.98) | 0.379   | 0.27 (0.01–21.4)  | 0.560   |
| Positive, strong expression       | 1   | 10.0                | 0.47 (0.02–9.85) | 0.627   | 0.36 (0.01–15.3)  | 0.592   |
| **pHSP27-Ser78 expression**       |    |                     |                  |        |                  |        |
| Negative                          | 50  | 10.5                | 1.00             |        | 1.00              |        |
| Positive, weak expression         | 12  | 8.0                 | 0.86 (0.11–6.35) | 0.875   | 1.35 (0.05–33.2)  | 0.856   |
| Positive, mild expression         | 9   | 11.0                | 0.85 (0.09–8.4)  | 0.888   | 0.99 (0.03–30.9)  | 0.995   |
| Positive, strong expression       | 6   | 9.5                 | 1.12 (0.14–10.4) | 0.872   | 6.23 (0.29–132.7) | 0.241   |
| **pHSP27-Ser82 expression**       |    |                     |                  |        |                  |        |
| Negative                          | 34  | 10.5                | 1.00             |        | 1.00              |        |
| Positive, weak expression         | 14  | 10.0                | 1.28 (0.07–25.2) | 0.873   | 2.88 (0.12–67.7)  | 0.521   |
| Positive, mild expression         | 23  | 8.0                 | 1.75 (0.09–35.3) | 0.715   | 1.95 (0.55–69.1)  | 0.713   |
| Positive, strong expression       | 6   | 11.0                | 1.09 (0.68–1.77) | 0.689   | 1.85 (0.06–53.1)  | 0.721   |
| **Gender**                        |    |                     |                  |        |                  |        |
| Male                              | 44  | 9.5                 | 1.00             |        | 1.00              |        |
| Female                            | 33  | 11.0                | 1.12 (0.49–2.55) | 0.789   | 0.91 (0.36–2.31)  | 0.844   |
| **Tumour size**                   |    |                     |                  |        |                  |        |
| <3.5 cm                           | 29  | 11.0                | 1.00             |        | 1.00              |        |
| >3.5 cm                           | 30  | 7.5                 | 2.39 (0.98–5.86) | 0.055   | 0.66 (0.26–1.71)  | 0.392   |
| **Tumour pathological stage**     |    |                     |                  |        |                  |        |
| T1                                | 6   | 21.5                | 1.00             |        | 1.00              |        |
| T2                                | 10  | 10.2                | 0.19 (0.03–1.48) | 0.113   | 0.06 (0.07–0.63)  | **0.019** |
| T3                                | 55  | 9.0                 | 0.49 (0.09–2.52) | 0.394   | 0.15 (0.2–1.26)   | **0.08**  |
| T4                                | 6   | 11.5                | 0.58 (0.17–2.03) | 0.394   | 0.42 (0.11–1.65)  | 0.215   |
| **Nodal status**                  |    |                     |                  |        |                  |        |
| N0                                | 16  | 19.0                | 1.00             |        | 1.00              |        |
| N1                                | 54  | 9.5                 | 0.14 (0.02–0.94) | **0.043** | 0.18 (0.03–1.16)  | 0.071   |
| N2                                | 7   | 3.0                 | 0.12 (0.04–0.37) | **0.001** | 0.08 (0.02–0.35)  | **0.001** |
| **Metastasis status**             |    |                     |                  |        |                  |        |
| M0                                | 49  | 11.0                | 1.00             |        | 1.00              |        |
| M1                                | 28  | 9.0                 | 0.48 (0.17–1.37) | 0.167   | 2.31 (0.75–7.07)  | 0.143   |
| **Tumour differentiation**        |    |                     |                  |        |                  |        |
| Well differentiated               | 4   | 32.5                | 1.00             |        | 1.00              |        |
| Moderately differentiated          | 19  | 12.0                | 1.47 (0.06–35.7) | 0.814   | 0.70 (0.02–21.4)  | 0.840   |
| Poorly differentiated              | 51  | 9.0                 | 6.79 (0.59–77.3) | 0.123   | 7.49 (0.59–95.1)  | 0.120   |
| Anaplastic                        | 3   | 1.0                 | 7.16 (0.71–72.1) | 0.095   | 7.70 (0.73–81.8)  | 0.090   |
| **Resection margin**              |    |                     |                  |        |                  |        |
| R0                                | 50  | 19.0                | 1.00             |        | 1.00              |        |
| R1                                | 27  | 10.5                | 0.31 (0.14–0.68) | **0.004** | 4.64 (1.62–13.3)  | **0.004** |
| **Lymphatic invasion**            |    |                     |                  |        |                  |        |
| L0                                | 28  | 13.5                | 1.00             |        | 1.00              |        |
Table 4 (continued)

| Variable                  | No | Median DFS [months] | Univariate Hazard ratio (95% CI) | p value | Multivariate Hazard ratio (95% CI) | p value |
|---------------------------|----|---------------------|----------------------------------|---------|----------------------------------|---------|
| L1                        | 49 | 9.0                 | 0.41 (0.13–1.29)                 | 0.126   | 3.28 (0.92–11.7)                 | 0.067   |
| Perineural invasion       |    |                     |                                  |         |                                  |         |
| Pn0                       | 6  | 22.0                | 1.00                             |         | 1.00                             |         |
| Pn1                       | 71 | 14.5                | 0.56 (0.82–3.90)                 | 0.562   | 0.13 (0.01–1.89)                 | 0.136   |
| Vascular invasion         |    |                     |                                  |         |                                  |         |
| V0                        | 33 | 17.0                | 1.00                             |         | 1.00                             |         |
| V1                        | 44 | 8.0                 | 2.63 (0.89–7.77)                 | 0.080   | 0.27 (0.09–0.84)                 | **0.023** |

CI confidence interval. All statistically significant variables are highlighted in bold.

Fig. 3 Kaplan–Meier curves for overall survival in the gemcitabine-treated subpopulation. 

- **a** HSP27: Strongly and mildly positive expression of HSP27 predicts a favourable OS in the non-metastasised and gemcitabine-treated patients, as compared to a negative or weakly positive protein expression (log-rank p value: 0.001). The median OS was 37.0 months in the group with a strongly positive expression and 30.0 months for a mildly positive expression. In contrast, the patients group with a negative expression had a median OS of 10.0 months. 

- **b** pHSP27-Ser15: The patients group with a negative expression of pHSP27-Ser15 had a median OS of 25.0 months. A comparable median OS was found in patients with a weakly positive (27.2 months) and mildly positive (29.0 months) expression (log-rank p value: 0.579). 

- **c** pHSP27-Ser78: No significant difference was found for the OS of pHSP27-Ser78 expression with a comparable median survival (negative: 25.0 months, weakly positive: 25.4 months, mildly positive: 27.4 months, strongly positive: 19.0 months, log-rank p value: 0.798). 

- **d** pHSP27-Ser82: The median OS was 30.2 months in patients with a negative expression, as compared with 25.0 months for a strongly positive expression with a non-significant log rank p value of 0.277.
Acknowledgements Open access funding provided by Semmelweis University (SE). This study was supported by a scientific grant from the Guenter Haenisch Foundation. The results were presented at the 13th Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), Amsterdam, The Netherlands, 2–5 June 2019. This work is part of the M.D. thesis of R. Drexler.

Compliance with ethical standards

Conflict of interest The authors declare they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Bostwick DG (2000) Immunohistochemical changes in prostate cancer after androgen deprivation therapy. Mol Urol 4(3):101–106 (discussion 107)

Butt E, Immel D, Meyer HE, Kotlyarov A, Laass K, Gaestel M (2001) Heat shock protein 27 Is a substrate of CGMP-dependent protein kinase in intact human platelets: phosphorylation-induced actin polymerization caused by HSP27 mutants. J Biol Chem 276(10):7108–7113

Cayado-Gutiérrez N, Moncalero VL, Rosales EM, Berón W, Salvaterra EE, Alvarez-Olmedo D, Radrizzani M, Ciocca DR (2013) Downregulation of Hsp27 (HSPB1) in MCF-7 human breast cancer cells induces upregulation of PTEN. Cell Stress Chaperones 18(2):243–249. https://doi.org/10.1007/s12921-012-0367-x

Choi DH, Ha JS, Lee WH, Song JK, Kim GY, Park JH, Cha HJ, Lee BJ, Park JW (2007) Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells. FEBS Lett 581(2007):1649–1656. https://doi.org/10.1016/j.febslet.2007.02.075

Ciocca DR, Calderwood SK (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10(2):86–103

Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul J-L et al (2007) Suppression of heat shock protein 27 expression promotes 5-fluorouracil sensitivity in colon cancer cells in a xenograft model. Oncol Rep 28:1269–1274. https://doi.org/10.3892/or.2012.1935

Elpek GO, Karaveli S, Simşek T, Keles N, Aksoy NH (2003) Expression of heat-shock proteins Hsp27, Hsp70 and Hsp90 in malignant epithelial tumour of the ovaries. APMIS Acta Pathol Microbiol Immunol Scand 111(4):523–530

Eto D, Hisata K, Horiiuchi H, Uchida S, Ishikawa H, Kawashima Y, Kinugasa T et al (2016) Expression of HSP27 in hepatocellular carcinoma. Anticancer Res 36(7):3775–3779

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403. https://doi.org/10.1016/j.ejca.2012.12.027

Gaestel M, Gross B, Benndorf R, Strauss M, Schunk WH, Kraft R, Otto A, Böhm H, Stahl J, Drabsch H (1989) Molecular cloning, sequencing and expression in Escherichia Coli of the 25-KDa growth-related protein of ehrlich ascites tumor and its homology to mammalian stress proteins. Eur J Biochem 179(1):209–213

Gaestel M, Schröder W, Benndorf R, Lippmann C, Buchner K, Hicho F, Erdmann VA, Bielka H (1991) Identification of the phosphorylation sites of the murine small heat shock protein Hsp25. J Biol Chem 266(22):14721–14724

Geisler JP, Geisler HE, Tammela J, Miller GA, Wiemann MC, Zhou Z (1999) A study of heat shock protein 27 in endometrial carcinoma. Gynecol Oncol 72(3):347–350. https://doi.org/10.1006/gyno.1998.5283

Guo Y, Ziesch A, Hocke S, Kampmann E, Ochs S, De Toni EN, Göke B, Gallmeier E (2015) Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis. J Cell Mol Med 19(2):340–350. https://doi.org/10.1111/jcmm.12444

Hayashi R, Ishii Y, Ochihi A, Matsuanga A, Endo T, Kitagawa Y (2012) Suppression of heat shock protein 27 expression promotes 5-fluorouracil sensitivity in colon cancer cells in a xenograft model. Oncol Rep 28:1269–1274. https://doi.org/10.3892/or.2012.1935

Ilic M, Ilic I (2016) Epidemiology of pancreatic cancer. World J Gastroenterol 22(44):9694–9705. https://doi.org/10.3748/wjg.v22.i44.9694

Jovevski B, Kelly MA, Rote AP, Berg T, Gastall HY, Justin LP, Benesch J, Aquilina A, Ecroyd H (2015) Phosphomimetics destabilize Hsp27 oligomeric assemblies and enhance chaperone activity. Chem Biol 22(2):186–195. https://doi.org/10.1016/j.chemb iol.2015.01.001

Kaemmerer D, Peter L, Lupp A, Schulz S, Sänger J, Baum RP, Prasad V, Hommann M (2012) Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol 5(3):187–194

Kang D, Choi HJ, Kang S, Kim SY, Hwang Y-S, Je S, Han Z, Kim J-H, Song JJ (2015) Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphascially acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells. Cell Signal 27(4):807–817. https://doi.org/10.1016/j.cellsig.2015.01.007

Kawano M, Kaino S, Amano S, Shindoh S, Suenaga S, Sen-Yo M, Sakaida I (2018) Heat shock protein 27 expression in EUS-FNA samples can predict gemcitabine sensitivity in pancreatic cancer. In Vivo 32(3):637–642. https://doi.org/10.21873/invivo.11286

Kostenko S, Moens U (2009) Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. Cell Mol Life Sci CMSL66(20):3289–3307. https://doi.org/10.1007/s00018-009-0886-3

Kuramitsu Y, Wang Y, Tabata K, Suenaga S, Ryoza S, Kaino S, Sakaida I, Nakamura K (2012) Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells. Anticancer Res 32(6):2295–2299

Lindquist S, Craig EA (1988) The heat-shock proteins. Annu Rev Biomed Genet 22:631–677. https://doi.org/10.1146/annurev.ge.22.12088.0830215

Springer
therapies enhances sensitivity to 5-FU chemotherapy in SW480 human colon cancer cells. Oncof Rep 39:1119–1124. https://doi.org/10.3892/oncr.2018.6180

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30. https://doi.org/10.3322/caac.21442

Taba K, Kuramitsu Y, Ryozawa S, Yoshida K, Tanaka T, Maehara S-I, Maehara Y, Sakaida I, Nakamura K (2010) Heat-shock protein 27 is phosphorylated in gemcitabine-resistant pancreatic cancer cells. Anticancer Res 30(7):2539–2543

Taba K, Kuramitsu Y, Ryozawa S, Yoshida K, Tanaka T, Mori-Iwamoto S, Maehara S-I, Maehara Y, Sakaida I, Nakamura K (2011) KNK437 downregulates heat shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine. Chemotherapy 57(1):12–16. https://doi.org/10.1159/000321019

Takeno S, Noguchi T, Kikuchi R, Sato T, Uchida Y, Yokoyama S (2001) Analysis of the survival period in resectable stage IV gastric cancer. Ann Surg Oncol 8(3):215–221

Têtu B, Brisson J, Landry J, Huot J (1995) Prognostic significance of heat-shock protein-27 in node-positive breast cancer: an immunohistochemical study. Breast Cancer Res Treat 36(1):93–97

Têtu B, Lacasse B, Bouchard HL, Lagacé R, Huot J, Landry J (1992) Prognostic influence of HSP-27 expression in malignant fibrohistiocytioma: a clinicopathological and immunohistochemical study. Can Res 52(8):2325–2328

Tsiaousidou A, Lambropoulou M, Chatzitheoklitos E, Tripsianis G, Tsompandii G, Simopoulos C, Tsarouchia AK (2013) B7H4, HSP27 and DJ-1 molecular markers as prognostic factors in pancreatic cancer. Panreatology 13(6):564–569. https://doi.org/10.1016/j.pan.2013.10.005

Uozaki H, Ishida T, Kakiuchi C, Horiiuchi G, Gotoh T, Iijima T, Imaura T, Machinami R (2000) Expression of heat shock proteins in osteosarcoma and its relationship to prognosis. Pathol Res Pract 196(10):665–673. https://doi.org/10.1053/s0344-0338(00)80118-1

Vahid S, Thaper D, Gibson KF, Bishop JL, Zoubeidi A (2016) Molecular chaperone Hsp27 regulates the Hippo tumour suppressor pathway in cancer. Nat Sci Rep. https://doi.org/10.1038/srep31842

Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (2011) Pancreatic cancer. Lancet 378(9791):607–620. https://doi.org/10.1016/S0140-6736(10)62307-0

Wu J, Liu T, Rios Z, Mei Q, Lin X, Cao S (2017) Heat shock proteins and cancer. Trends Pharmacol Sci 38(3):226–256. https://doi.org/10.1016/j.tips.2016.11.009

Xu L, Chen S, Bergan RC (2006) MAPKAPK2 and HSP27 are downstream effectors of P38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 25(21):2987–2998. https://doi.org/10.1038/sj.onc.1209337

Yang F, Jin C, Fu DL, Warshaw AL (2019) Modified FOLFIRINOX for resected pancreatic cancer: opportunities and challenges. World J Gastroenterol 25(23):2839–2845. https://doi.org/10.3748/wjg.v25.i23.2839

Zoubeidi A, Gleave M (2012) Small heat shock proteins in cancer therapy and prognosis. Int J Biochem Cell Biol 44(10):1646–1656. https://doi.org/10.1016/j.biocel.2012.04.010

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.